Rx License-Rx

TAB-2760

Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities

This CDC invention entails methods and apparatuses for in situ testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Ophthalmology

Indication: Ophthalmology

Modality: Cell/Gene Therapy

Focus tags: Ophthalmology, Oncology, Infectious Disease, Cardiometabolic, Inflammation

Technology tags: Cell/Gene Therapy, Biologic, Diagnostic / Biomarker

Mechanism:

Development stage: Early / Discovery

Patent status: Abandoned

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Ophthalmology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with National Institutes of Health. The practical first use case is Ophthalmology. Public description: This CDC invention entails methods and apparatuses for in situ testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Ophthalmology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Ophthalmology

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.